PE Tech Report


Like this article?

Sign up to our free newsletter

SK Capital sells IBA Molecular to CapVest

SK Capital (SK), a private investment firm focused on the specialty materials, chemicals and healthcare sectors, is to sell IBA Molecular (IBAM) to funds advised by CapVest Partners LP (CapVest). The transaction is expected to close at the end of Q1 2016.

IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe and Asia. IBAM has a unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalised medicine and making molecular imaging/therapy a major discipline in healthcare.
 The Company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications SA.
Jamshid Keynejad, Chairman of IBA Molecular and a Founding Partner of SK Capital, says, “We are proud of what has been accomplished by IBA Molecular under our ownership and believe that the business has significant growth ahead under the continued leadership of Renaud Dehareng and his team. We are confident that CapVest will be a strong partner for IBAM as it moves into the next stage of its development. We wish CapVest, the management team and IBAM’s employees every success and are excited to follow their accomplishments in the years to come.”

Like this article? Sign up to our free newsletter